[Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes].
Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation.
Larsen
Claus Morten
CM
Steno Diabetes Center, Universitets Hospitalet, Zürich, Universitet i Lund, og Karolinska Institutet, Stockholm. cmla@steno.dk
Faulenbach
Mirjam
M
Vaag
Allan
A
Vølund
Aage
A
Ehses
Jan
J
Seifert
Burkhardt
B
Mandrup-Poulsen
Thomas
T
Donath
Marc
M